Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Lawyers who believe commission will be more lenient toward mergers under the Bush Administration "will be doing their actual or potential clients a big disservice if those clients act on that presumption," FTC Chairman Timothy Muris asserted at American Bar Association Antitrust Section annual meeting in Chicago Aug. 7. "If you come in with transactions that would not fly in the past, you are likely to crash unless you have compelling, stubborn facts on your side," he noted. FTC has been busy with pharma recently; it considered requiring Glaxo Wellcome and SmithKline Beecham to divest one of their smoking cessation products before approving their merger and also oversaw Pfizer's acquisition of Warner-Lambert. Muris took over as head of FTC June 4 (1"The Tan Sheet" June 4, p. 2)

You may also be interested in...


Drug patents should not be listed in Orange Book by FDA if they claim unapproved aspects of a drug, commission suggests in May 16 citizen petition to agency. "Any patent claiming only an unapproved component, an unapproved formulation or an unapproved use of a drug product" should not be allowed in Orange Book, FTC says. Petition comes in response to complaints from generic drug manufacturers that innovator companies are filing large numbers of late-listed patents to thwart private label competition. FTC is conducting an inquiry into this and other anticompetitive practices in drug industry (1"The Tan Sheet" Oct. 16, 2000, p. 13)

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts